Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS-502
- Development stage
- Preclinical
- Lead developer
- Amyloid Solution
- Modality
- Small Molecules
01
Overview
AS-502 is a small-molecule brain delivery platform being developed by Amyloid Solution. It is specifically designed to facilitate or enhance the transport of therapeutic agents across the blood-brain barrier (BBB) to improve the treatment of central nervous system disorders, with a primary focus on Alzheimer's disease. The platform aims to overcome the physiological challenges of CNS drug delivery by improving the brain penetration of various payloads. As of the latest reports, AS-502 is in the lead optimization stage of preclinical development. The specific molecular mechanism or transporter targeted by the platform has not been publicly disclosed by the developer.
Beyond the preview
Go deeper on AS-502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS-502.